Agios Pharmaceuticals, Inc. (AGIO)

Trade AGIO now with
4/1/2021 7:17:35 AM Agios Closes Sale Of Commercial, Clinical And Research-stage Oncology Portfolio To Servier
12/1/2020 7:17:25 AM Agios: Phase 3 ACTIVATE Trial Of Mitapivat Met Its Primary Endpoint
11/12/2020 4:58:37 PM Agios Says FDA Orphan Drug Designation Granted To Mitapivat For Treatment Of Sickle Cell Disease
9/8/2020 4:15:45 PM Agios Appoints Jonathan Biller As CFO
5/19/2020 7:18:58 AM Agios Pharma Says The Lancet Oncology Publishes Data From Global Phase 3 ClarIDHy Study Of TIBSOVO
3/23/2020 7:13:03 AM Agios Says FDA Cleared Investigational New Drug Application For AG-946
1/12/2020 8:06:42 PM Agios Expects To Have 4 Marketed Products In At Least 8 Indications, At Least 6 Molecules In Development In 2025
11/7/2019 9:57:55 PM Agios Prices Underwritten Public Offering Of 8.25 Mln Shares At $31.00/shr
10/9/2019 7:08:58 AM Agios To Present Data From AG-270 Phase 1 Dose-Escalation Study At AACR-NCI-EORTC International Conference
9/10/2019 7:05:23 AM Agios To Present Phase 3 ClarIDHy Study Data Of TIBSOV At ESMO
2/25/2019 7:20:06 AM Agios Pharma Presents Updated Data From Phase 1 Study Of Ivosidenib In Combination With Azacitidine
2/20/2019 7:05:15 AM Agios Announces FDA Acceptance Of SNDA For TIBSOVO
11/16/2018 7:07:03 AM Agios Pharma Presents Updated Data From Ongoing Phase 1 Study Of Single Agent AG-881 In Advanced Glioma